GenMark Diagnostics (GNMK) : During the past 4 weeks, traders have been relatively bearish on GenMark Diagnostics (GNMK), hence the stock is down -4.48% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.53% relative to the S&P 500. The 4-week change in the price of the stock is -3.5% and the stock has fallen -4.48% in the past 1 week.
The stock has recorded a 20-day Moving Average of 4.3% and the 50-Day Moving Average is 0.94%. GenMark Diagnostics (NASDAQ:GNMK): On Fridays trading session , Opening price of the stock was $9.51 with an intraday high of $9.54. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $9.33. However, the stock managed to close at $9.38, a loss of 1.16% for the day. On the previous day, the stock had closed at $9.49. The total traded volume of the day was 661,689 shares.
The company Insiders own 7.09% of GenMark Diagnostics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.72% . During last six month period, the net percent change held by insiders has seen a change of -1.86%. Also, JP Morgan maintains their rating on the shares of GenMark Diagnostics (NASDAQ:GNMK). The current rating of the shares is Overweight. Equity Analysts at the Firm raises the price target to $13 per share from $10 per share. The rating by the firm was issued on July 29, 2016.
GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company is focused on developing and commercializing its eSensor detection technology. The Companys electrochemical technology enables detection of multiple distinct biomarkers in a single sample. The Companys XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular research and diagnostic tests with a workstation and disposable test cartridges. Its XT-8 system supports up to 24 independent test cartridges, each of which can be run independently, resulting in a workflow for its focused customers, which are primarily hospitals and reference laboratories. It has an installed base of approximately 540 XT-8 analyzers, or placements, with its customers.